Publications

Intracluster correlation coefficients in the Greater Mekong Subregion for sample size calculations of cluster randomized malaria trials

Peerawaranun P. et al, (2019), Malaria Journal, 18

The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos

von Seidlein L. et al, (2019), Malaria Journal, 18

Corrigendum to: Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.

Taylor WRJ. et al, (2019), The Journal of infectious diseases

Safety, pharmacokinetics, and mosquito-lethal effects of ivermectin in combination with dihydroartemisinin-piperaquine and primaquine in healthy adult Thai subjects.

Kobylinski KC. et al, (2019), Clinical pharmacology and therapeutics

Delivery of long-term-injectable agents for TB by lay carers: pragmatic randomised trial.

Cohen DB. et al, (2019), Thorax

The temporal dynamics of humoral immunity to Rickettsia typhi infection in murine typhus patients.

Phakhounthong K. et al, (2019), Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

Determinants of treatment failure among tuberculosis patients in Kandahar City, Afghanistan: A 5-year retrospective cohort study.

Rahimi BA. et al, (2019), International journal of mycobacteriology, 8, 359 - 365

Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.

Taylor WRJ. et al, (2019), The Journal of infectious diseases

Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study

van der Pluijm RW. et al, (2019), The Lancet Infectious Diseases, 19, 952 - 961

Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: an open label non-randomized interventional trial.

Sevene E. et al, (2019), Malaria journal, 18

Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers

von Seidlein L. et al, (2019), Human Vaccines & Immunotherapeutics, 1 - 9

Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults.

Hanboonkunupakarn B. et al, (2019), Antimicrobial agents and chemotherapy, 63

Systematic review of analytical methods applied to longitudinal studies of malaria.

Stanley CC. et al, (2019), Malaria journal, 18

Efficacy and safety of artemether-lumefantrine as treatment for Plasmodium falciparum uncomplicated malaria in adult patients on efavirenz-based antiretroviral therapy in Zambia: an open label non-randomized interventional trial.

Banda CG. et al, (2019), Malaria journal, 18

The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians.

Dysoley L. et al, (2019), BMC infectious diseases, 19

Peste des Petits Ruminants ( PPR ) virus serological surveillance in goats in Lao PDR : Issues for disease eradication in a low‐resource disease‐free setting

Burns RJL. et al, (2019), Transboundary and Emerging Diseases, 66, 939 - 947

The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial

von Seidlein L. et al, (2019), PLOS Medicine, 16, e1002745 - e1002745

Effect of point-of-care C-reactive protein testing on antibiotic prescription in febrile patients attending primary care in Thailand and Myanmar: an open-label, randomised, controlled trial

Althaus T. et al, (2019), The Lancet Global Health, 7, e119 - e131

Effectiveness and safety of 3 and 5 day courses of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar

Tun KM. et al, (2018), Malaria Journal, 17

Identifying risk factors for the development of sepsis during adult severe malaria

Njim T. et al, (2018), Malaria Journal, 17